Aztreonam (lysine)
Based on 20 publication(s) in Google Scholar
Aztreonam (lysine) is a monocyclic beta-lactam antibiotic, and has a very high affinity for penicillin-binding protein 3 (PBP-3). Aztreonam (lysine) is active against Gram-negative aerobic bacteria.
For research use only. We do not sell to patients.
- CAS No.: 827611-49-4
- Formula: C19H31N7O10S2
- Molecular Weight:581.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Aztreonam (lysine)
More- Cell. 2024 Feb 15;187(4):882-896.e17 [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Pharmaceutics. 2023 Nov 30;15(12):2705. [Abstract]
- Biomater Adv. 2024 Sep 3:166:214027. [Abstract]
- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Antimicrob Agents Chemother. 2026 Mar 23:e0186025. [Abstract]
- Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. [Abstract]
- J Antimicrob Chemother. 2026 Jan 19;81(2):dkaf495. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2025 Oct 27:dkaf388. [Abstract]
- Water. 2025 Jun 6.
- Infect Drug Resist. 2026 May 8;19.
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- Curr Microbiol. 2021 Dec 14;79(1):12. [Abstract]
- Res Sq. 2026 Mar 9.
- Patent. US20230110378A1.
All Antibiotic Isoforms
More
Biological Activity
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 827611-49-4
-
Molecular Weight 581.62
-
Formula C19H31N7O10S2
-
SMILES
N[C@@H](CCCCN)C(O)=O.CC(C)(O/N=C(C1=CSC(N)=N1)\C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cell
Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. [Abstract]2024 Feb 15;187(4):882-896.e17 PMID: 38295787 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Pharmaceutics
2023 Nov 30;15(12):2705. PMID: 38140046 -
Biomater Adv
Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections - Development and in-vitro characterization. [Abstract]2024 Sep 3:166:214027. PMID: 39255571 -
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Antimicrob Agents Chemother
Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. [Abstract]2026 Mar 23:e0186025. PMID: 41870042 -
Antimicrob Agents Chemother
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]2018 Jul 27;62(8). pii: e00414-18. PMID: 29760136 -
J Antimicrob Chemother
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies. [Abstract]2026 Jan 19;81(2):dkaf495. PMID: 41549665 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model. [Abstract]2025 Oct 27:dkaf388. PMID: 41140026 -
-
-
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
Curr Microbiol
Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]2021 Dec 14;79(1):12. PMID: 34905092 -
-
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)